Sprin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sprin

Quick Facts

Property Description
Active ingredient Permethrin
Form Topical preparations (cream, lotion, shampoo)
Pharmacological class Ectoparasiticide
General purpose Elimination of parasitic mites and lice
Origin Synthetic pyrethroid

Sprin: Defining the Drug and Its Pharmacological Class

Sprin is a medication whose active component is Permethrin, and it belongs to the high-level pharmacological class known as an ectoparasiticide. This classification means its singular, fundamental purpose is to combat and eliminate ectoparasites, which are small organisms that infest the body's external surfaces. As a specialized scabicide and pediculicide, its primary therapeutic use is restricted to addressing infestations caused by mites (scabies) and lice (pediculosis). The established importance of Permethrin in public health, particularly for controlling these parasitic conditions, is clinically recognized, reflecting its status as an essential medicine for a basic healthcare system.


Permethrin: Composition, Origin, and Dosage Form

The active ingredient Permethrin is a synthetic pyrethroid, a compound structurally derived from the natural insecticides found in chrysanthemum flowers but manufactured through controlled chemical synthesis. This product is consistently formulated as a single active ingredient and is exclusively available as a topical preparation, ensuring a defined route of administration via application directly to the skin or scalp. Common variations of its dosage form include a cream, lotion emulsion, or shampoo base, with the selection determined by the specific infestation being targeted.


General Benefit: How Sprin Works at a High Level

Sprin functions by exerting a potent, targeted neurotoxic effect solely against the parasitic organisms, rather than affecting human physiology in the same manner. This mechanism principle involves disrupting the parasite's nervous system, which rapidly leads to its paralysis and subsequent death of ectoparasites. The general benefit of using Sprin is the swift and conclusive eradication of the parasitic population responsible for the infestation, effectively ending the infectious cycle and the associated irritation.

Regulatory References

  1. WHO Model List of Essential Medicines
  2. NIH Bookshelf
  3. NIH

What side effects are possible with Sprin?

Possible Side Effects and Safety Information

The official safety profile for topical Sprin (Permethrin) is primarily characterized by localized reactions, which are classified and reported according to standard regulatory frequency frameworks, such as those used by the FDA and EMA. The documented adverse reactions fall into specific System-Organ-Classes (SOCs), with the most frequent effects involving the skin.


Adverse Reaction Classification

Frequency Category Representative Adverse Reaction
Common (ge 1/100) Burning, Stinging, Pruritus (Itching)
Uncommon (ge 1/1000 to <1/100) Erythema (Redness), Numbness, Tingling

These common effects are often mild and transient, occurring predominantly at the application site. Other reported effects, which appear under Nervous System or Gastrointestinal Disorders SOCs, include headache, dizziness, abdominal pain, nausea, and vomiting.


Serious Reactions and Safety Constraints

Serious adverse reactions documented in regulatory sources center on Hypersensitivity (allergic reactions) to any of the product's components, including the active ingredient, synthetic pyrethroids, or pyrethrins. The medicine is contraindicated in patients with a known hypersensitivity to these substances. Extremely uncommon post-marketing reports of seizure have been noted, though regulatory bodies have not medically confirmed them as associated with the treatment when used as directed.

Population-Specific Safety Notes

The official labeling includes specific safety considerations for vulnerable populations. The product is not established as safe and effective for infants less than two months of age. Regarding use during pregnancy, Permethrin topical is assigned Pregnancy Category B by the FDA, based on animal studies showing no evidence of harm. For nursing mothers, regulatory documents note that it is not known if the drug is excreted in human milk, advising caution.

Overdose and Emergency Response

Officially documented manifestations of Sprin (Aspirin) overdose include early symptoms such as tinnitus (ringing in the ears), hearing loss, nausea, and vomiting. These initial signs are often accompanied by hyperventilation (rapid or deep breathing), headache, and confusion, as stated in regulatory labeling.

Any suspected overdose necessitates seeking immediate medical attention or contacting a Poison Control Center right away, as explicitly mandated by government health authorities. Urgent medical evaluation is critical even if initial symptoms are mild or absent.

Severe overdose is associated with life-threatening outcomes that require hospitalization, including seizures, cerebral edema, respiratory failure, and profound acid-base disturbances (metabolic acidosis). Due to the lack of a known specific antidote, management focuses on supportive care and officially described procedures.

These procedures include gastrointestinal decontamination, intravenous fluid replacement, and urinary alkalinization to enhance elimination. In severe cases, hemodialysis may be required. Furthermore, official documents note that chronic toxicity, often involving non-specific symptoms like subtle confusion or fever, is a documented concern, particularly in older adults.

Therapeutic Uses of Sprin

What Sprin Treats: Main Uses and Benefits

Sprin (Aspirin) is used across several major therapeutic domains. It is relevant when supportive symptom management is appropriate and contributes to easing the overall symptom load in conditions characterized by periods of heightened symptoms.


Supportive Care for Cardiovascular Health

Sprin is commonly used across conditions characterized by periods of heightened symptoms related to the cardiovascular system. It is applied across domains where additional symptomatic support is needed in contexts involving heightened systemic burden. This medication may assist with maintaining functional stability in situations involving certain distressing symptoms.

Symptomatic Relief for Pain and Discomfort

This medicine is applied in areas where short-term symptom management is appropriate, particularly for helping to address symptom clusters that may become intense or disruptive. Sprin is relevant for easing symptoms related to systemic imbalance, including headache, mild body aches, and inflammatory or irritative states. It offers symptomatic relief that helps patients cope more steadily with symptom fluctuations.


Quick Facts

  • Support for Systemic Discomfort: Sprin is relevant for easing symptoms related to systemic imbalance, such as fever.
  • Acute Symptom Management: Applied in areas where short-term symptom management for issues like headache and body aches is appropriate.

Regulatory References

  1. Aspirin: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Sprin?

The official regulatory profile for Sprin (Permethrin topical) strictly defines which populations are eligible to use the medicine and which are prohibited.

Eligibility and Contraindications

Classification Population or Condition
Approved Use Adults, adolescents, and children two months of age and older.
Contraindicated Individuals with a known hypersensitivity to Permethrin or any related compound, such as a synthetic pyrethroid or pyrethrin.
Contraindicated Infants less than two months of age, as safety and effectiveness have not been established in this group.

Restricted and Conditional Use

Use of Sprin is restricted during certain physiological states. The drug is classified under the former FDA Pregnancy Category B and should only be used if clearly needed. For breastfeeding mothers, official labeling advises consideration of temporarily discontinuing nursing or withholding the drug. Furthermore, application is strictly limited; the product is not for use in eyes or on other mucous membranes. Official labeling provides no specific information regarding use in patients with severe hepatic or renal impairment.

What should I know about interactions with other medicines?

The interaction profile for Sprin (Permethrin) is defined by its topical route of administration, which results in minimal systemic absorption of the active ingredient. Official regulatory documents, including those from the FDA and EMA, state that there are no known interactions with other systemic medicinal products. This classification reflects a low risk for pharmacokinetic or pharmacodynamic drug-drug interactions when compared to medicines taken orally.

The only formal restriction detailed in official labeling concerns pharmacodynamic interference with specific concurrent treatments. Specifically, treatment of eczematous-like skin reactions with corticosteroids should be withheld prior to the use of Sprin. This is a mandatory administration-timing rule designed to prevent the corticosteroid from reducing the local immune response and potentially leading to an exacerbation of the underlying parasitic infestation. This constraint is procedural and is not a contraindication based on systemic toxicity. Furthermore, official regulatory information confirms that no known interactions exist with food, alcohol, or herbal products. The overall interaction profile is characterized by the absence of systemic drug-drug interactions and a single, critical procedural constraint for co-management of skin conditions.

Mechanism of Action

How Sprin Works


Direct Modulation of Parasite Sodium Channels

This domain describes the primary action of the active ingredient, Permethrin, which acts as a modulator on the voltage-gated sodium channels (VGSCs) within the neuronal membranes of ectoparasites. By binding to the open state of these channels, the drug prevents them from closing, leading to a sustained and massive influx of sodium ions that forces the nerve cell into a state of persistent depolarization.


The Cascade to Paralysis and Systemic Failure

The persistent depolarization initiates an uncontrollable barrage of electrical signals throughout the entire parasite nervous system, causing extreme hyper-excitation that immediately disrupts all motor functions. This systemic neurological disruption is the defining mechanistic cascade that results in rapid, involuntary muscular spasms, leading quickly to paralysis of the target organism, which is the mechanism’s final physiological consequence.


Selectivity and Constraints on Efficacy

The mechanism is highly selective, as human VGSCs are far less sensitive to the drug's action, and the human body rapidly metabolizes the compound, confining its neurotoxic effect to the parasite's physiological system. However, the mechanism's efficacy is constrained by parasite resistance, which occurs when genetic mutations change the structure of the VGSC, or when the parasite increases its production of detoxification enzymes (like GST) to degrade the drug.

Dosage and Administration Information

Sprin (acetylsalicylic acid) tablets should be taken exactly as prescribed by your healthcare professional. The dose and duration of therapy are determined by your medical condition and therapeutic needs, such as the prevention of cardiovascular events like heart attack or stroke. This medicine should only be used for cardiovascular conditions under a doctor's supervision.

Administration Instructions

  • Swallow the tablet whole with a full glass of water. Do not crush, chew, or break the tablet unless specifically instructed by your healthcare provider. Some formulations may be chewable, but this must be confirmed with your doctor or the product's label.
  • You may take the tablet with or after food to help reduce the potential for stomach upset or irritation, a common side effect of acetylsalicylic acid.
  • If you take this medicine daily, maintain a consistent dosing schedule, taking it at the same time each day to help keep a steady level of the medicine in your body.

Dose Management

  • Never alter your prescribed dose or stop taking Sprin without first consulting your doctor, even if you feel better. Sudden discontinuation of therapy may increase your risk of a cardiovascular event.
  • If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not take two doses at once to make up for a missed one.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sprin (Permethrin)

Evidence for Use in Mites (Scabies) Infestation

The primary research for Sprin (Permethrin 5% cream) for the study of scabies involves randomized controlled trials (RCTs) and comprehensive systematic reviews. These studies were used in research exploring outcomes related to the clearance of parasitic mites. Researchers monitored a primary outcome known as the clinical cure rate, which measured the status of the mites and the change in associated skin symptoms over a defined time interval. These findings contribute to the broader evidence landscape for conditions characterized by scabies infestations.

Studies reported measurements of parasite clearance in trial participants, and research highlighted that adherence to the application protocol was a factor considered in the measured outcomes. The evidence is limited regarding long-term outcomes tracking the durability of parasite clearance beyond the initial follow-up period of four weeks, and data for certain groups, such as individuals with severe immunosuppression, remain insufficient to draw broad conclusions.

Evidence for Use in Lice (Pediculosis) Infestation

For the study of lice infestations, research has mainly focused on randomized controlled trials (RCTs) using Permethrin 1% preparations. The studies explored two main outcomes: the status of live lice, and the measured ovicidal efficacy (the ability to monitor eggs). Research monitored the status of live lice across different populations, describing outcomes measured at the conclusion of the treatment period.

A key area of uncertainty relates to the geographic variation in findings. Studies conducted in different areas have reported varying patterns in measured outcomes, indicating that certain populations of lice can appear to have reduced susceptibility to Permethrin preparations. Long-term effects are not fully established, as follow-up durations were typically limited to only one to two weeks post-treatment. Additionally, data are still emerging regarding the measured outcomes in cases of re-infestation.

Key Studies & References

  1. Permethrin Versus Benzyl Benzoate for the Treatment of Scabies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
  2. Evidence and recommendations on scabies - Guidelines on the Treatment of Skin and Oral HIV-Associated Conditions in Children and Adults (WHO/NCBI)
  3. Therapeutic potential of plant-based therapies in pediculosis capitis: Systematic review and meta-analysis (Includes Permethrin Resistance Data)

Frequently Asked Questions (FAQ)

Common questions about Sprin (FAQ)

Q: Can Sprin be taken by older adults?

A: Official product information indicates that the safety and effectiveness are supported by data used for approval in adults and children two months of age and older. Regulatory documents do not specify a separate dose or a distinct safety profile specifically for the elderly (geriatric population) compared to other adults.


Q: Is it true that Sprin is related to 'drug X'?

A: The active ingredient in Sprin, Permethrin, is a compound structurally classified as a synthetic pyrethroid. This high-level chemical class indicates its structural relationship to a large group of synthetic compounds that are derived from natural insecticides found in chrysanthemum flowers.


Q: Is Sprin a type of narcotic or controlled substance?

A: No. Official regulatory scheduling confirms that Sprin (Permethrin topical) is not classified as a narcotic, nor is it listed as a controlled substance by regulatory agencies.


Q: What happens if I miss a time to use Sprin?

A: Sprin topical preparations are generally intended for a single, complete application to treat the infestation. If an infestation remains after the required time following the first application, official documents describe that a second application may be considered.


Q: Does taking Sprin affect my ability to drive?

A: According to official product labeling, Sprin is stated to have no or negligible influence on a person’s ability to drive or operate machinery. This is consistent with the product's classification as having no or negligible influence on functional ability.


Q: Are there long-term effects associated with using Sprin?

A: Official documents indicate that research follow-up is typically limited to one to four weeks after treatment. Data tracking long-term effects or the sustained durability of parasite clearance beyond this initial short-term period are not broadly available.


Q: Can people with liver problems use Sprin?

A: Official labeling provides no specific information or guidance for the use of Sprin in patients who have severe hepatic (liver) or renal (kidney) impairment.


Q: Is a metallic taste in the mouth a possible side effect of Sprin?

A: Official regulatory documents that list adverse reactions include some effects on the digestive system, such as nausea or abdominal pain. However, a metallic taste is not listed among the common, uncommon, or rare side effects described in the product’s safety documentation.


Q: Is Sprin safe for use in adolescents or children?

A: Regulatory documents describe the product as established for use in adults, adolescents, and children two months of age and older. It is explicitly contraindicated (should not be used) for infants who are younger than two months old.


Q: Are there known interactions between Sprin and common supplements like vitamins?

A: Due to its topical route of administration, official regulatory documents confirm that there are no known systemic interactions between Sprin and food, alcohol, herbal products, or other systemic medicines. This general classification includes common vitamin and mineral supplements.


Q: Is there a generic version of Sprin available?

A: The active ingredient, Permethrin, is a well-established medication. It is available from multiple manufacturers under both brand names and generic names in various topical forms.


Q: How is Sprin cleared from the body?

A: When Sprin is absorbed into the body, it is broken down by natural enzymes called esterases. It is then quickly eliminated from the body, primarily through the urine, as compounds that are no longer active.


Q: Is Sprin a relatively new drug or has it been around for a long time?

A: The active ingredient, Permethrin, is a well-established medicine. Its inclusion on the World Health Organization's (WHO) Model List of Essential Medicines confirms its established role in healthcare.


Q: Can Sprin cause changes in mood or sleep patterns?

A: Official safety data lists specific reactions under the category of Nervous System Disorders, such as headache and dizziness. However, changes in a person's mood or sleep patterns are not listed as common or uncommon adverse reactions in the official safety profile.

How should Sprin be stored and disposed of?

How to Store and Dispose of Sprin (Permethrin)

Permethrin preparations must be stored according to strict regulatory guidelines to maintain stability and ensure safety.

Storage Requirements

Condition Official Requirement
Temperature Store at Controlled Room Temperature, generally 15^circ to 30 C (59^circ to 86 F), but do not freeze [Source 1.6, 1.4].
Protection Protect from direct light and excessive heat [Source 2.6, 2.7].
Child Safety Keep out of the sight and reach of children [Source 1.4, 2.6].
Packaging Keep the container tightly closed and store in the original container [Source 2.2, 2.7].

Disposal Instructions

Unused or expired product must be disposed of through an approved waste disposal facility consistent with local, state, and national regulations [Source 2.9]. Permethrin is toxic to aquatic life; therefore, the product must not be poured down drains or released into waterways [Source 2.5, 2.8].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sprin found in:

A-Z Index: